Delivery Order SPE2DB22D3004-SPE2DB25FPZ69

Award Date 3/21/25
Potential Completion Date 3/24/25
Potential Value $3.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Firm Fixed Price Delivery Order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,239.87, is for the supply of Gadavist 10 MMOL/10 ML vials, with a period of performance through December 14, 2023. This contract is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running through November 2026....
This is a $1,704.90 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of Gadavist 1 mmol/ml bulk vials, a pharmaceutical product. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $4,455.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp., a major pharmaceutical distributor. The contract is for the delivery of Gadavist, a 10 mmol/10 ml vial medication, with a performance period through May 14, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, AmerisourceBergen Drug Corporation, a subsidiary of AmerisourceBergen Corporation. The delivery order, valued at $1,573.54, is for the supply of Gadavist 10 mmol/10 ml vial, a pharmaceutical product, to support military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,942.00, is for the procurement of Gadavist, a 10 milliliters per vial medical product, with a performance period through January 8, 2024. This contract award is associated with Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,052.45 firm fixed-price delivery order is for the medical product "GADAVIST 10 MMOL/10 ML VIAL 10ML" and has a period of performance through November 14, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Gadavist 1 mmol/ml bulk vials (30 ml). The contract has a firm fixed price of $1,704.90 and an ultimate completion date of March 28, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as the primary...
This federal contract award is for the supply of the pharmaceutical product Gadavist (7.5 mmol/7.5 ml vial, 7.5 ml) to the Defense Logistics Agency (DLA). The $1,071.13 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, and does not have a set-aside designation. The contract has an ultimate completion date of September 13, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This is a $1,040.96 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is to supply the drug Gadavist, a contrast agent used in medical imaging procedures. The delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,834.97 firm fixed-price delivery order is for Gadavist 10 mmol/10 ml vials. The contract has an ultimate completion date of November 27, 2024 and was awarded on November 26, 2024. This award is a part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides...
  • SPE2DB22D3004
    Indefinite Delivery Contract
  • SPE2DB22D3004-SPE2DB25FPZ69
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract valued at $3,377.44 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide the drug Gadavist 10 mmol/10 ml vial 10 ml. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition. This order will support the healthcare needs of military personnel, veterans, and other federal beneficiaries through the DLA's procurement of essential pharmaceutical products.

Generated 6/21/25, 9:58 AM